Hematologic relapse in AL amyloidosis after high-dose melphalan and stem cell transplantation
Author:
Affiliation:
1. Amyloidosis Center, Boston University School of Medicine, Boston, MA;
2. Section of Hematology and Oncology, Boston Medical Center, Boston MA; and
3. Department of Biostatistics, Boston University School of Public Health, Boston, MA
Publisher
American Society of Hematology
Subject
Cell Biology,Hematology,Immunology,Biochemistry
Link
http://ashpublications.org/blood/article-pdf/130/11/1383/1402285/blood788729.pdf
Reference9 articles.
1. Update on treatment of light chain amyloidosis;Mahmood;Haematologica,2014
2. Molecular mechanisms of amyloidosis;Merlini;N Engl J Med,2003
3. Long-term outcome of patients with AL amyloidosis treated with high-dose melphalan and stem cell transplantation: 20-year experience;Sanchorawala;Blood,2015
4. Outcome of AL amyloidosis after high-dose melphalan and autologous stem cell transplantation: long-term results in a series of 421 patients;Cibeira;Blood,2011
5. Long-term event-free and overall survival after risk-adapted melphalan and SCT for systemic light chain amyloidosis;Landau;Leukemia,2017
Cited by 30 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Hematopoietic Cell Transplantation in Light Chain Amyloidosis;Manual of Hematopoietic Cell Transplantation and Cellular Therapies;2024
2. Risk factors, treatments and outcomes of patients with light chain amyloidosis who relapse after autologous stem cell transplantation;Bone Marrow Transplantation;2023-12-26
3. Immunoglobulin light chain amyloidosis: 2024 update on diagnosis, prognosis, and treatment;American Journal of Hematology;2023-12-14
4. Exploiting endogenous and therapy-induced apoptotic vulnerabilities in immunoglobulin light chain amyloidosis with BH3 mimetics;Nature Communications;2022-10-02
5. Kappa chain amyloidosis: a deadly entity not to forget in patients with nondiabetic proteinuria;Gazzetta Medica Italiana Archivio per le Scienze Mediche;2022-10
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3